SIGLEC1 and neoplasm: There, the tumor-associated macrophages (TAMs) acquire the M2 phenotype corresponding to alternatively activated macrophages, characterized by having high levels of CD169, CD206, and CD204 (or SR1A) [79] and promote the initiation and progression of NSCLC [80] by secreting various anti-inflammatory cytokines, activating signaling pathways, and interacting with other immune cells [81].